Previous 10 | Next 10 |
SCOTTSDALE, Ariz., Dec. 07, 2021 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (NADSAQ: DERM), a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological c...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
SCOTTSDALE, Ariz., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (NADSAQ: DERM), a partner company of Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), expanded the company’s board of directors as part of its recent in...
SCOTTSDALE, Ariz., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological c...
SCOTTSDALE, Ariz., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological c...
SCOTTSDALE, Ariz., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”), a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, and ...
Sanofi has seen an increase in third quarter sales on a constant currency basis. Looking deeper, there was strong growth both in Dupixent, a medication for atopic dermatitis (eczema) and flu vaccine. The pharmaceutical group continues to suffer from disruption in normal care as a ...
Following up on its initial announcements in January and February , Incyte (NASDAQ: INCY ) reports detailed results from two successful Phase 3 clinical trials, TRuE-AD1 and TRuE-AD2 , evaluating a topical cream formulation of kinase inhibitor ruxolitinib in adolescents and adults wi...
Merger activity increased last week with five new deals announced and one deal closing. The new deals announced last week were across different sectors. Two of the five new deals belong to the financial services sector, one from the real estate sector and two from the technology sector. Acco...
Diabetes treatment was once a major part of drugmaker Sanofi (NASDAQ: SNY) , with its blockbuster Lantus bringing in $7 billion in annual sales as recently as six years ago. These days, Lantus' annual sales are more in the area of $3.2 billion, and in December, the company announced it w...
News, Short Squeeze, Breakout and More Instantly...
Journey Medical Corporation Company Name:
DERM Stock Symbol:
NASDAQ Market:
Journey Medical Corporation Website:
DALLAS, TX / ACCESSWIRE / July 17, 2024 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small and mid-sized commercial-stage companies, today provided a corporate progress update as well as a summary of the achieve...
SCOTTSDALE, Ariz., July 11, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescriptio...
Journey Medical Corporation (NASDAQ: DERM) is the focus of IBN's latest stock spotlight. The company's shares have moved -1.78% on the day to $5.51. Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological condi...